Market Place
Sourcing Support
All News #Library
Biotech
Catalym Initiates Phase 2B Trial For Visugromab Combo
02 Dec 2025 //
BUSINESSWIRE
CatalYm Ph1/2a Data Shows Durable Visugromab Responses at ESMO
20 Oct 2025 //
BUSINESSWIRE
CatalYm’s Visugromab Combo Shows Strong Ph2 Bladder Results
17 Oct 2025 //
BUSINESSWIRE
Catalym Initiates Phase 2b Trial For Visugromab Combo
30 Sep 2025 //
BUSINESSWIRE
CatalYm Reports Ph 2 Bladder Cancer Trial Results at ESMO
22 Sep 2025 //
BUSINESSWIRE
CatalYm Leadership Changes to Boost Visugromab Development
15 Sep 2025 //
BUSINESSWIRE
CatalYm to Present Data on GDF-15 Blockade at AACR 2025
25 Apr 2025 //
BUSINESSWIRE
CatalYm Names Scott Clarke CEO & Begins Visugromab Phase 2b
09 Jan 2025 //
BUSINESSWIRE
CatalYm`s Visugromab Published In Nature On Checkpoint Resistance
11 Dec 2024 //
BUSINESSWIRE
CatalYm Presents Visugromab’s Potential In Cancer Cachexia
10 Dec 2024 //
BUSINESSWIRE
CatalYm`s Visugromab/Nivolumab Combo Shows Responses In Late-Line Cancers
02 Jun 2024 //
BUSINESSWIRE
Catalym Gdf-15 Visugromab Positive: Ph2a Nsclc Urothelial Hcc Asco 2024
23 May 2024 //
BUSINESSWIRE
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC
06 Dec 2023 //
BUSINESSWIRE
German biotech’s efforts to revive obesity target yield positive PhIIa results
06 Dec 2023 //
ENDPTS
CatalYm commences Dosing in a Phase 2 Study with Visugromab
26 Oct 2023 //
BUSINESSWIRE
CatalYm to Present Phase 2a Data on Visugromab
25 May 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.